Background: Ferric carboxymaltose (FCM) treatment in case of iron deficient (ID) patients with chronic heart failure (CHF) has shown great promise according to the findings of recent studies in improvement of symptoms and quality of life, New York Heart Association (NYHA) classification, and exercise capacity. Aim of the study: The purpose of the current study is to assess the budget impact of treating CHF patients with FCM in a sample of Romanian hospitals. Material and methods: Calculations have been based on the budget impact model developed by Theidel et al. The assumptions and clinical outcomes of the current study were based on a multivariate statistical approach used in the same German study. The predicted outcomes were based on data pooled from four double-blind randomized controlled trials. The time horizon of the model was 1 year.
INTRODuCTION
Chronic heart failure (CHF) is a complex, malignant clinical syndrome, resulting in the heart's inability to provide proper output. In spite of the continuous development of new therapies addressed to CHF, the mortality of this disease remains very high, and the episodes of acute decompensation leading to acute pulmonary edema are quite frequent. As a result, the number of hospital readmissions in emergency conditions is increasing, which directly impacts the cost of healthcare in this patient population. The symptoms vary depending on which ventricle is affected. Common signs and symptoms include dyspnea, coughing, wheezing, lower extremity edema, fatigue, nausea, and palpitation. 1 In developed countries, the lifetime risk of chronic heart failure for men and women is 1 in 5, the risks being as high for women as for men. 2 In order to assess the severity of CHF, it is recommended to use the New York Heart Association (NYHA) functional classification, which is important for the diagnosis and management of the disease, as well as setting a prognosis. 3 In Romania, heart failure (HF) can be considered a severe condition, resulting in high mortality and readmission rates. According to the published literature regarding the epidemiological data on CHF in Romania, 4.7% of the population over the age of 35 is diagnosed with the disease. The 1-year mortality for hospitalized CHF patients has been estimated to 6%, and 8.9% of the patients are readmitted. 4 There is no HF registry in Romania, as there is in other countries; however, there have been several studies assessing the local situation. Recent estimates show an incidence of 0.146% and a prevalence of 1.76% for CHF, with an approximate number of 800,000-900,000 patients. 5 The incidence of CHF is continually increasing, which may be the result of the aging of the population and the increase of the survival of myocardial infarction patients. 6 Iron deficiency (ID) is an important comorbidity of CHF.
A pooled analysis of 1,506 patients has found that about 50% of CHF patients are iron-deficient, and ID has been found to be connected to the severity of CHF (expressed in NYHA classification). 7 8 Further studies have found that iron homeostasis disorders are correlated with NYHA class, an increased risk of anemia, and the progression of CHF. 9 Another study of 546 patients has concluded that in case of systolic CHF, ID is quite common, and it represents a predictor for a negative outcome. 10 The health-related quality of life (HRQoL) of CHF patients is also affected by ID. A study of 552 patients has found that the HRQoL of ID patients is significantly worse compared to non-ID CHF patients, especially because of the negative impact on the physical dimensions of health. 11 Various treatment options are accepted in case of ID patients; however, intravenous iron is usually preferred.
A meta-analysis of two studies has shown that, when compared to placebo, the intravenous ferric carboxymaltose (FCM) treatment of CHF patients with ID results in the reduction of hospitalizations due to worsening CHF. 12 
METHODS
We performed cost measurement analysis in 8 Romanian hospitals, of different size/category and of various geographical locations. Of these 8 public hospitals 3 are town/ city hospitals, 3 county/municipal hospitals, and 2 clinical hospitals.
In Romania, the financing of hospitalized patients is Patient selection from these hospitals has been based on the ICD-10 diagnosis codes for heart failure, regardless whether the diagnosis of chronic heart failure was primary or secondary. At this stage we did not separate the patients who received FCM during their hospitalization from those who did not, as the volume of drugs administered in the selected hospitals was negligible.
The calculations are based on the actual dosage used in the Romanian medical setting. However, additional calculations were performed to include the study dosage of 1,679 mg FCM.
Hospitalized patient population
The main scope of the analysis is to assess the total cost of the treatment of CHF patients according to NYHA class.
Based on the patient selection criteria, a total number of 8,494 patients have been included in the study. Table 1 represents their distribution according to the treating institution and NYHA class. This patient population was used only for the direct cost measurement in order to adapt the German study to the costs specific to the Romanian healthcare system.
MODEL INPuTS

CliniCal output parameters
The key clinical parameters were based on the data used by the budget impact model of Theidel et al. 17 The key clinical outcomes to feed the BIM are the probabilities for the patients to be in a specific NYHA class (derived from the multivariate statistical analysis), death over time, rate of hospitalization due to the worsening CHF, and average length of stay (ALOS). All these data have been taken from the BIM model of Theidel et al.
eConomiC parameters
Cost of FCM treatment and the impact of Clawback
For the budget impact calculations, the wholesaler price of FCM has been used as an input of the model.
As a special situation in case of the financing of the Romanian healthcare system, when it comes to the costs of drugs and medication, there is a special tax that needs to be taken into calculation: the Clawback tax, applied to all drugs and medication. The objective of this tax is to maintain the drugs and medication expenditure of the NHIH at a sustainable level. The expenditure above a specific threshold needs to be paid back by the pharmaceutical companies to the NHIH in the form of this tax. Since this is a more specific case, the budget impact calculations have been performed in two scenarios: both with and without this tax.
In order to calculate the exact cost for the public payer, 
Cost of outpatient visit
In order to determine the cost of an outpatient visit, a panel of experts has been interviewed, resulting in a list of services provided per each NYHA class. The following cost elements have been taken into account for the cost The cost of the outpatient visit has been calculated based on actual cost data instead of the reimbursement fee paid by the NHIH, for each cost element.
Cost of home visits
The cost of a home visit has been determined at a value of €7.16, the reimbursement fee of the NHIH for healthcare services of this kind, as no direct cost data was available.
Cost of hospitalization due to CHF worsening
The cost of hospitalization has been calculated based on actual cost data from 8 hospitals (2 clinical level Each case of CHF has been identified in these 8 hospitals for the period analyzed, resource use was attributed to these cases, and unit costs were attributed according to the resource use. The NYHA class was known for each case, thus costs could be calculated according to the NYHA class.
The cost of hospitalization also included the cost of one-day hospitalization, which was calculated based on actual hospital costs.
Cost of medication per year
The yearly medication cost of CHF patients has been cal- 
RESuLTS
results of tHe budget impaCt model using real world dosage data
The total cost of the treatment of 1,000 CHF patients without FCM has been €641,588 without the Clawback tax ( influence on the financial outcome of the budget impact calculations. This was run for both scenarios, with and without applying the Clawback tax (Figure 1 and Figure 2 ). 
DISCuSSION
This is the first study to assess the budget impact of the 25 In case of this study with a time horizon of 24 weeks, based on the FAIR-HF trial, the ICER has been of $22,192, but it is still lower than the NICE threshold. Cost-effectiveness studies are a crucial aspect of decision-making, and such analysis could be performed in Romania based on the findings of the present study.
In comparison with the majority of these studies, the present study follows a period of 52 weeks, based on the CONFIRM-HF study.
Iron deficiency is an important comorbidity in CHF, Another limitation of the study is the use of direct reimbursement fees as costs in case of outpatient care, as there is no information regarding the actual costs of this type of care.
CONCLuSIONS
By treating patients with FCM, the signs and symptoms of CHF can be improved, and the duration and frequency of hospitalizations can be reduced. This added clinical benefit can be achieved at a cost of €37 per patient for the no-Clawback scenario and a cost reduction of €9 for the Clawback scenario. Our analysis confirms that the unmet need of CHF patients with ID can be met by the treatment with FCM at a minimal additional cost.
